Dr.Mahesh Pathak, P15057
A prospective study on 60 patients of allergic conjunctivitis. Aim was to study the response of different concentrations of Olopatadine available in market. Patients were selected of allergic conjunctivitis between age group of 10–20 years. Slit lamp examination was done in all patients to diagnose allergic conjunctivitis. Patients already on treatment, any systemic anti allergic medications, vernal keratoconjunctivitis or limbitis were excluded. Patients were divided into 3 groups, i.e. olopatadine 0.1%, 0.2% and 0.77%. Specific questionnaire was made to assess their response and was filled at 1 and 3 months followup. Results: All groups had symptomatic relief with first 2 groups showing non-significant difference. Group 1 and 2 when compared to group 3 showed significant difference in favour of group 3 at 1month, but at 3months it was non-significant. Conclusion: All concentrations of olopatadine are equally effective with long term use but 0.77% concentration showed early benefits.
Leave a Comment